BridgeBio Pharma (BBIO) Gains from Investment Securities (2021 - 2023)
BridgeBio Pharma (BBIO) reported Gains from Investment Securities of -$1.0 million for Q4 2023, down 928.8% on a YoY basis from $125000.0 in Q4 2022, and down 478.1% sequentially from $274000.0 in Q3 2023.
BridgeBio Pharma (BBIO) Gains from Investment Securities (2021 - 2023) Analysis & Trends
BridgeBio Pharma (BBIO) has 3 years of Gains from Investment Securities data on file, last reported at -$1.0 million in Q4 2023.
- For the quarter ending Q4 2023, Gains from Investment Securities fell 928.8% year-over-year to -$1.0 million; the trailing twelve-month figure through Dec 2023 stood at -$984000.0 (down 108.74% YoY), and the FY2023 full-year result was -$984000.0, down 162.64% from the prior year.
- Gains from Investment Securities retreated to -$1.0 million in Q4 2023, from $274000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $10.2 million in Q2 2022 to a low of -$1.0 million in Q4 2023.
- A 3-year average of $1.0 million and a median of $125000.0 in 2022 frame the typical range for Gains from Investment Securities.
- Across the five-year window, Gains from Investment Securities jumped 815.04% in 2022 and slumped 928.8% in 2023, its largest moves.
- Tracing BBIO's Gains from Investment Securities over 3 years: stood at $738000.0 in 2021, then tumbled by 83.06% to $125000.0 in 2022, then tumbled by 928.8% to -$1.0 million in 2023.
- Business Quant data shows BBIO's Gains from Investment Securities at -$1.0 million in Q4 2023, $274000.0 in Q3 2023, and -$111000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | BridgeBio Pharma | 16.41 Bn | 15.47 Bn | 184.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -1.04 Mn |
| Dec 31, 2023 | -1.04 Mn |
| Sep 30, 2023 | 274,000.00 |
| Sep 30, 2023 | 274,000.00 |
| Jun 30, 2023 | -111,000.00 |
| Jun 30, 2023 | -111,000.00 |
| Mar 31, 2023 | -111,000.00 |
| Mar 31, 2023 | -111,000.00 |
| Dec 31, 2022 | 125,000.00 |
| Dec 31, 2022 | 125,000.00 |
| Sep 30, 2022 | 56,000.00 |
| Sep 30, 2022 | 56,000.00 |
| Jun 30, 2022 | 10.22 Mn |
| Jun 30, 2022 | 10.22 Mn |
| Mar 31, 2022 | 852,000.00 |
| Mar 31, 2022 | 852,000.00 |
| Dec 31, 2021 | 738,000.00 |
| Dec 31, 2021 | 738,000.00 |
| Sep 30, 2021 | -658,000.00 |
| Sep 30, 2021 | -658,000.00 |